Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466074 | 0.84 | AOC3 (0.49) | AOC3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10201419 | 0.84 | APP (0.46) | HTR1AADRA1DADRA1AADRA1BFFAR1 | |
| SCHEMBL19461646 | 0.80 | LIPE (0.51) | AOC3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23301902 | 0.77 | GABRA5 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10200177 | 0.77 | L3MBTL1 (0.50) | AOC3FFAR1MAPK1MAPTL3MBTL1 | |
| SCHEMBL29755761 | 0.77 | GABRA5 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16783083 | 0.77 | AOC3 (0.48) | AOC3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16048596 | 0.76 | ALOX5 (0.51) | HTR1AADRA1DADRA1AADRA1BMRGPRX4 | |
| SCHEMBL21240944 | 0.75 | GABRG2 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1935936 | 0.74 | GABRG2 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| CN-107250110-B | Novel compounds as inhibitors of transfection Rearrangement (RET) | 葛兰素史克知识产权发展有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-9879021-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-30 | — | — | US | disclosed |
| US-20150099762-A1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099762-A1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8937071-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-20 | — | — | US | disclosed |
| US-8937071-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-20 | — | — | US | disclosed |
| US-8937071-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-20 | — | — | US | disclosed |
| WO-2014141187-A1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014141187-A1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | RET, FER, THRB | AOC3 3910/4885GABRP 1308/4885GABRD 2159/4885 |
| US-20150099762-A1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | AOC3 3910/4885GABRP 1308/4885GABRD 2159/4885 |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | AOC3 4171/4885GABRP 1512/4885GABRD 2356/4885 |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | AOC3 4171/4885GABRP 1512/4885GABRD 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.